EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, announced today that they believe their recently patented (U.S. Pat. #9,216,386) treatment methodology, in conjunction with pending provisional patent applications, can be effectively used in treating Zika, and Dengue as well as other serious viruses. Premier, together with their Brazilian JV partner, Auramedi, are working to accelerate their research efforts in this area.
Mitchell S. Felder, MD, Premier Biomedical’s Scientific Advisory Board Chairman said, “We believe that by lowering the viral load on the mother’s system, her own immune system can better fight the virus in her body and therefore, that of her fetus, thereby increasing the chances of her delivering a normal, healthy baby without microcephaly. The larger the viral load on the mother, the higher the chances of her baby having severe disabilities or being still-born.”
Future testing is planned to prove out the effectiveness of Premier’s patented process on treating viruses.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, initially targeting the treatment of cancer. The Company's common stock trades on the Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.